Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

126
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
126
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

317
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
317
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

85
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
85
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

135
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
135
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model01:14

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

124
The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A...
124

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systems biology during 20 years of PLoS Computational Biology.

PLoS computational biology·2026
Same author

Purifying circRNA by ultrafiltration with membranes having well-defined pores.

Separation and purification technology·2026
Same author

LFCT: A Benchmark Dataset for Low-Frame-Rate Cell Tracking in Long-Term Live-Cell Microscopy.

bioRxiv : the preprint server for biology·2026
Same author

Introduction to Single-cell Physiologically-Based Pharmacokinetic (scPBPK) Models.

bioRxiv : the preprint server for biology·2026
Same author

Serial Imaging of Tumour and microEnvironment (SITE) platform for live-cell <i>ex vivo</i> modelling of primary and metastatic cancer dynamics.

bioRxiv : the preprint server for biology·2025
Same author

Purifying circular RNA by ultrafiltration.

Separation and purification technology·2025

Related Experiment Video

Updated: Apr 14, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.8K

Network pharmacodynamic models for customized cancer therapy.

James M Gallo1, Marc R Birtwistle1

  • 1Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Wiley Interdisciplinary Reviews. Systems Biology and Medicine
|April 28, 2015
PubMed
Summary

Enhanced PD models, integrating pharmacokinetics, offer personalized anticancer therapies by modeling individual patient profiles. Despite challenges, these PK/ePD models promise customized drug regimens for improved treatment outcomes.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

7.3K

Related Experiment Videos

Last Updated: Apr 14, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.8K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

7.3K

Area of Science:

  • Pharmacology and Systems Biology
  • Computational Biology and Bioinformatics

Background:

  • Traditional pharmacokinetics (PK) and pharmacodynamics (PD) modeling primarily used plasma drug concentrations.
  • Limited tissue sample availability historically constrained model development and therapeutic drug monitoring.
  • Advances in systems biology and pharmacology led to the development of enhanced PD (ePD) models.

Purpose of the Study:

  • To explore the role of enhanced PD (ePD) models in advancing personalized anticancer therapies.
  • To discuss the integration of PK and ePD models for sophisticated multidrug regimen design.
  • To identify challenges and future prospects of ePD and PK/ePD models in clinical application.

Main Methods:

  • Development of ePD models based on mechanistically grounded biochemical reaction networks.
  • Representation of models as systems of coupled ordinary differential equations.
  • Tailoring model parameters to individual genomic and proteomic profiles for personalized therapy.

Main Results:

  • ePD models enable the incorporation of patient-specific genetic and protein abnormalities.
  • Linking PK models with ePD models provides comprehensive pharmacological simulation tools.
  • These integrated models facilitate the design of sophisticated multidrug regimens for cancer treatment.

Conclusions:

  • ePD and PK/ePD models represent a significant step towards personalized anticancer drug therapy.
  • Challenges in model identifiability, scaling, and parameter estimation need to be addressed.
  • Continued technological evolution and innovative implementation strategies will enhance the viability of these models for customized cancer treatment.